Boston, MA, 03/11/2014 – According to the Zacks Research firm, C&J Energy Services Inc (NYSE:CJES) has entered into an overbought territory and therefore, has advised caution for its investors to tread carefully. The research firm noted that though the company has reported positive gains of late, but it has come to a RSI value of 71.3. As a result, C&J Energy Services Inc (NYSE:CJES) is being placed under rank 5 by the research company, which implies ‘strong sell’.
Kearny Financial Corp.(NASDAQ:KRNY) has been marching up ahead for the past few days and according to the research firm Zacks, it will continue to do so in the coming days as well. The analyst at the Zacks equity research has assigned a ‘buy’ rating to it for now. Recently, the Fairfield-based bank operator, confirmed that it will buy a small Brooklyn based bank as part of its expansion plan. Kearny Financial Corp.(NASDAQ:KRNY) currently has 41 bank branches and aggregate $3.2 billion in assets.
Vitesse Semiconductor Corp (NASDAQ:VTSS), which is a pioneer in advanced IC solutions for Enterprise as well as Carrier announced on Monday that it has joined Broadband Forum. It is noteworthy that Broadband Forum is considered as one of the leading industry consortium, which comprises of more than 200 equipment manufacturers, service providers as well as other organizations. Vitesse Semiconductor Corp (NASDAQ:VTSS) works as a non-profit industry organization, with its focus centered around engineering faster and smarter broadband network. The Forum helps to shape up the future of packet-based Ethernet networks through assisting service providers to align their broadband network deployments.
Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) declared on Monday that it intends to offer its common stock shares for sale through an underwritten public offering so as to raise a total gross proceeds of nearly $60 million. The company is expected to offer underwriters with another 30-day window to purchase additional shares of the offering in order to cover allotments. The net proceeds of the offering are aimed to be utilized for the development and advancement of products through clinical trials and towards other general corporate purposes.